Earnings Update: Pacific Biosciences of California, Inc. (NASDAQ:PACB) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Simply Wall St.11-09

Last week, you might have seen that Pacific Biosciences of California, Inc. (NASDAQ:PACB) released its third-quarter result to the market. The early response was not positive, with shares down 5.7% to...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2482758425?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dC75hPkPk1wNzUHQ29Af1A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3","is_english":true,"pubTime":"2024-11-09 21:17","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2482758425","market":"us","top_or_hot":-1,"title":"Earnings Update: Pacific Biosciences of California, Inc. (NASDAQ:PACB) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts","media":"Simply Wall St.","content":"<div>\n<p>Last week, you might have seen that Pacific Biosciences of California, Inc. (NASDAQ:PACB) released its third-quarter result to the market. The early response was not positive, with shares down 5.7% to...</p>\n\n<a href=\"https://finance.yahoo.com/news/earnings-pacific-biosciences-california-inc-131747324.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Earnings Update: Pacific Biosciences of California, Inc. (NASDAQ:PACB) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEarnings Update: Pacific Biosciences of California, Inc. (NASDAQ:PACB) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-09 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/earnings-pacific-biosciences-california-inc-131747324.html><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week, you might have seen that Pacific Biosciences of California, Inc. (NASDAQ:PACB) released its third-quarter result to the market. The early response was not positive, with shares down 5.7% to...</p>\n\n<a href=\"https://finance.yahoo.com/news/earnings-pacific-biosciences-california-inc-131747324.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PACB","symbol_name":"Pacific Biosciences of Californi","start_time":0,"source_url":"https://finance.yahoo.com/news/earnings-pacific-biosciences-california-inc-131747324.html","article_id":"2482758425","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dC75hPkPk1wNzUHQ29Af1A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482758425","pubTimestamp":1731158267,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Last week, you might have seen that Pacific Biosciences of California, Inc.  released its third-quarter result to the market. The early response was not positive, with shares down 5.7% to US$2.30 in the past week. It was a moderately negative result overall - revenue fell 4.5% short of analyst estimates at US$40m, although at least statutory losses were marginally smaller than expected, at US$0.22 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PACB":"Pacific Biosciences of Californi",".IXIC":"NASDAQ Composite","NDAQ":"纳斯达克OMX交易所"},"translate_title":"盈利更新：加州太平洋生物科学公司（纳斯达克：PACB）刚刚公布了第三季度业绩，分析师正在更新他们的预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{".IXIC":1,"NDAQ":1,"PACB":1},"content_text":"Last week, you might have seen that Pacific Biosciences of California, Inc. (NASDAQ:PACB) released its third-quarter result to the market. The early response was not positive, with shares down 5.7% to US$2.30 in the past week. It was a moderately negative result overall - revenue fell 4.5% short of analyst estimates at US$40m, although at least statutory losses were marginally smaller than expected, at US$0.22 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year. \n View our latest analysis for Pacific Biosciences of California \n\n\n\n  NasdaqGS:PACB Earnings and Revenue Growth November 9th 2024\n \n\n After the latest results, the 13 analysts covering Pacific Biosciences of California are now predicting revenues of US$205.0m in 2025. If met, this would reflect a meaningful 18% improvement in revenue compared to the last 12 months. Losses are predicted to fall substantially, shrinking 52% to US$0.70. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$212.4m and losses of US$0.71 per share in 2025. \n The consensus price target was broadly unchanged at US$3.07, implying that the business is performing roughly in line with expectations, despite a downwards adjustment to forecast revenue next year. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic Pacific Biosciences of California analyst has a price target of US$7.00 per share, while the most pessimistic values it at US$2.00. So we wouldn't be assigning too much credibility to analyst price targets in this case, because there are clearly some widely different views on what kind of performance this business can generate. With this in mind, we wouldn't rely too heavily the consensus price target, as it is just an average and analysts clearly have some deeply divergent views on the business. \n Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We would highlight that Pacific Biosciences of California's revenue growth is expected to slow, with the forecast 14% annualised growth rate until the end of 2025 being well below the historical 19% p.a. growth over the last five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 6.5% per year. So it's pretty clear that, while Pacific Biosciences of California's revenue growth is expected to slow, it's still expected to grow faster than the industry itself. \nThe Bottom Line \n The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Regrettably, they also downgraded their revenue estimates, but the latest forecasts still imply the business will grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. \n Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for Pacific Biosciences of California going out to 2026, and you can see them free on our platform here. \n Plus, you should also learn about the   3 warning signs  we've spotted with Pacific Biosciences of California (including 1 which is significant) . \nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482758425"}